Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluate the Safety and Efficacy of ALLN-177 in Patients With Enteric Hyperoxaluria: A Phase III Randomized, Placebo-Controlled Study

Next Previous
Trial Profile

Evaluate the Safety and Efficacy of ALLN-177 in Patients With Enteric Hyperoxaluria: A Phase III Randomized, Placebo-Controlled Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Reloxaliase (Primary)
  • Indications Hyperoxaluria
  • Focus Registrational; Therapeutic Use
  • Acronyms URIROX-1
  • Sponsors Allena Pharmaceuticals

    • Most Recent Events

    • 04 Jan 2022 According to an Allena Pharmaceuticals media release, data from this study are expected to be published during the first half of 2022.
    • 09 Mar 2021 According to an Allena Pharmaceuticals media release, patients will also continue to be followed for a minimum of two years to confirm clinical benefit, including the ability of reloxaliase to reduce the incidence and severity of kidney stone disease and renal impairment, to support potential accelerated approval.
    • 13 May 2020 According to an Allena Pharmaceuticals media release, a late-breaking abstract detailing kidney stone risk and its association with urinary oxalate levels in patients with enteric hyperoxaluria was accepted for presentation as part of the American Urological Association (AUA) Virtual Education Experience, which is being held in place of the cancelled AUA 2020 Annual Meeting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top